A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in Patients with Metastatic Solid Tumors
Details
Age
Adult
Eligibility
Part 2 Expansion will enroll only pancreatic cancer, colorectal cancer and cholangiocarcinoma
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Wells Messersmith, MD
Study ID
Protocol Number: 20-2976
More information available at ClinicalTrials.gov: NCT04666688
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers